Serum Adropin Levels Research Articles

Association of plant-based diets with adropin, atherogenic index of plasma, and metabolic syndrome and its components: A cross-sectional study on adults.

Little is known about the association of plant-based diet indices with metabolic syndrome (MetS) and its novel predictive biomarkers, including the atherogenic index of plasma (AIP) and adropin. We aimed to investigate the association of plant-based diets with adropin, atherogenic index of plasma, and MetS and its components in adults. The present population-based cross-sectional study was conducted on a representative sample of adults aged 20-60 years in Isfahan, Iran. Dietary intake was obtained through a validated 168-item semi-quantitative food frequency questionnaire (FFQ). Peripheral blood was obtained after an overnight fast of at least 12 h from each participant. MetS was identified based on the Joint Interim Statement (JIS). AIP was calculated as a logarithmically transformed ratio of triglyceride (TG)/high-density lipoprotein cholesterol (HDL-c), and serum levels of adropin were measured by an ELISA kit. A total of 28.7% of subjects had MetS. No significant association was found between the overall plant-based diet index (PDI) and the healthful plant-based diet index (hPDI) with MetS. However, a non-linear association was observed between hPDI and MetS. Subjects in the third quartile of the unhealthful plant-based diet index (uPDI) had higher odds of MetS compared to the first quartile (OR: 2.39; 95% CI: 1.01, 5.66). The highest quartile of PDI (OR: 0.46; 95% CI: 0.21, 0.97) and the third quartile of hPDI (OR: 0.40; 95% CI: 0.18, 0.89) were associated with decreased odds of having high-risk AIP compared to the first quartile, after adjusting for potential confounders. No linear association was found between quartiles of plant-based diet indices and serum levels of adropin. Plant-based diet index (PDI) and hPDI were not associated with the prevalence of MetS in adults, while moderate adherence to uPDI increased the prevalence of MetS. In addition, high adherence to PDI and moderate adherence to hPDI were associated with decreased odds of high-risk AIP. No significant association was found between plant-based diet indices and serum adropin levels. To confirm these findings, further studies with prospective designs are warranted.

Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies

ObjectiveAdropin, a newly identified regulatory protein has garnered attention given its potential role in metabolism regulation, especially glucose metabolism and insulin resistance. However, studies on the association between adropin and type 2 diabetes mellitus (T2DM) are equivocal. The aim of this study is to assess the association between serum adropin levels and T2DM using a systematic review and meta-analysis of observational studies.MethodsPubMed, Scopus, ISI Web of science, and Google Scholar were searched, up to August 2022, for studies that reported the association between serum levels of adropin in adults with T2DM compared to a control group without diabetes. A random-effect model was used to compute the pooled weighted mean difference (WMD) with 95% confidence intervals (CI).ResultsMeta-analysis of 15 studies (n = 2813 participants) revealed that the serum adropin concentrations were significantly lower in patients with T2DM compared with the control group (WMD= -0.60 ng/mL, 95% CI: -0.70 to -0.49; I2 = 99.5%). Subgroup analysis also found lower concentration of adropin in patients with T2DM who were otherwise healthy compared to a control group (n = 9; WMD=-0.04 ng/ml, 95% CI= -0.06 to -0.01, p = 0.002; I2 = 96.4).ConclusionsOur study showed adropin levels are lower in patients with diabetes compared to a control group without diabetes. However, the limitations of observational studies challenge the validity of the results, and further investigations are needed to confirm the veracity of these findings and additionally explore possible mechanisms.

The Relationship Between Coronary Collateral Circulation and Serum Adropin Levels.

Objective Coronary collateral circulation (CCC) are vascular structures that limit the infarct area, protect left ventricular function, and reduce the frequency of arrhythmia and mortality during myocardial ischemia and infarction. In this study, we examined the relationship between the development of CCC and serum adropin levels, which has been shown in previous studies to regulate endothelial functions and increase endothelial nitric oxide synthesis,in patients with acute myocardial infarction. Methods This study included 41 patients with insufficient CCC and 43 patients with well-developed CCC who were hospitalized for acute myocardial infarction and underwent coronary angiography. The Cohen-Rentrop classification was used to grade the CCC. The patients were divided into two groups according toRentrop grades: those with a 0-1 stage were considered as insufficientand those withgrades of 2-3 were considered as well-developed CCC. We took blood samples to measure the adropin levels within the first 24 hours of hospitalization. Results The mean age was 59.1±11.9 yearsand62 (73.8%)were male. The right coronary artery was the most frequently target vessel (n: 51, 60.7%), and the majority of the patients presented with ST-segment elevation myocardial infarction (STEMI) (n:58, 69%). The median interval between the severe chest pain and the intervention was significantly higher in patients with well-developed CCC (p=0.042). The serum adropin levels in patients with insufficient CCC were significantly lower than in those with well-developed CCC(196.3 [131.5 - 837.0] pg/mL vs. 235.5 [171.9 - 1124.2] pg/mL, p<0.001). Logistic regression analysis revealed that the circumflex artery as the target vessel, NSTEMI (non-STEMI) as the type of myocardial infarction, and serum adropin level were the independent risk factors for the prediction of poor coronary collateral vessel formation (p<0.05). Conclusions In this study, we found that in patients with acute myocardial infarction, those with well-developed CCC had higheradropin levels.

Relation Between Adropin Levels and Hyperhomocysteinemia in Patients with Coronary Artery Disease

Background and aim: Homocysteine and adropin effects on endothelial function are antagonistic. The current study aimed to evaluate the association between serum levels of adropin and homocysteine and the severity of coronary artery disease (CAD) . Patients and methods: This cross-sectional study included 86 patients submitted to coronary angiography with ≥ 50% stenosis in one or more coronary arteries. Serum Adropin and homocysteine levels were estimated. The anatomical synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) score was utilized to assess the severity of CAD. Results: According to serum homocysteine levels, they were classified into patients with normal homocysteine levels (GI; n=54) and patients with hyperhomocysteinemia (GII; n=32). Comparison between the studied groups regarding clinical and laboratory findings revealed that GI patients had significantly shorter duration of diabetes (3.8 ± 5.3 versus 8.2 ± 7.5 years, p=0.009), higher serum triglycerides levels (204.7 ± 99.6 versus 142.9 ± 55.6 mg/dL, p=0.002), lower HbA1c levels (7.2 ± 1.6 versus 8.2 ± 2.0%; p = 0.013) and significantly higher adropin levels (7.4 ± 2.5 versus 1.6 ±1.0, p

Association Between Serum Adropin Level and Cardiac Target Organ Damages in Patients Undergoing Invasive Coronary Angiography

Association Between Serum Adropin Level and Cardiac Target Organ Damages in Patients Undergoing Invasive Coronary Angiography

Serum Adropin Level in the Early Period of ST-Elevation Myocardial Infarction and Its Relationship With Cobalamin and Folic Acid.

Studies on biomarkers in the diagnosis of myocardial infarction are ongoing. Adropin is a biomarker that has been studied and has been shown to have different effects. This study aimed to examine the adropin level of patients with myocardial infarction within the first 24 hours, as well as its relationship with cobalamin and folic acid. The control group included 70 patients whose troponin values did not increase and no coronary lesions were detected. In the ST-elevation myocardial infarction (STEMI) group, 70 patients with ST elevation on ECG and coronary total thrombosis on coronary angiography were evaluated. Coronary lesion severity was measured using the SYNergy between the percutaneous coronary intervention (PCI) with TAXUS and Cardiac Surgery (SYNTAX) score tool. Hemogram, troponin, adropin, C-reactive protein (CRP), cobalamin, folic acid, and other biochemical parameters were evaluated in all patients. In the STEMI group, a significant increase was observed in the adropin level along with the troponin and CRP levels in the first 24 hours (p<0.001). Cobalamin and folic acid levels were low in the same group (p:0.016, p<0.001). While a strong negative correlation was observed between adropin and cobalamin, no correlation was found with other parameters. The study supports that adropin could be used as a cardiac biomarker in the early stages of STEMI patients. Another result is with low cobalamin and folic acid levels in patients with myocardial infarction which needs to be further explained with the strong negative correlation between adropin and cobalamin.

Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes

BackgroundAdropin is a potent metabolic regulator of insulin sensitivity and glycolipid metabolism. The present study investigated the effects of sitagliptin on adropin and metabolic parameters in participants with newly diagnosed type 2 diabetes (T2D).MethodsThirty-five participants newly-diagnosed with T2D were prescribed sitagliptin 100 mg once daily for 17 weeks. Twenty-eight age-, sex-, and BMI-matched healthy subjects were included as the control group. Adropin and clinical parameters were assessed at baseline and after treatment.ResultsAt baseline, serum adropin levels were lower in T2D participants than in the healthy individuals (3.12 ± 0.73 vs. 5.90 ± 1.22 ng/ml, P < 0.01). Serum adropin levels were significantly higher in T2D patients after sitagliptin treatment (4.97 ± 1.01 vs. 3.12 ± 0.73 ng/ml, P < 0.01). The changes in serum adropin levels after sitagliptin treatment were associated with the improvements of fasting blood glucose (FBG) (β = − 0.71, P < 0.01), glycosylated hemoglobin (HbA1c) (β = − 0.44, P < 0.01) and homeostatic model assessment of β-cell function (HOMA-β) (β = 9.02, P < 0.01).ConclusionsSitagliptin treatment could significantly increase serum adropin levels in participants with newly diagnosed T2D. The increase in serum adropin levels could be associated with the amelioration of glucose metabolism, which might be involved in beneficial glucose-lowering mechanisms of sitagliptin.Trial registrationClinicaltrials.gov, NCT04495881. Retrospectively registered on 03/08/2020.

Investigation of the relationship between serum adropin levels, oxidative stress biomarkers, and blood pressure in DOCA-salt hypertensive rats

Background/Aim: Adropin is involved in the pathophysiology and development of cardiovascular diseases, such as hypertension. The aim of this study was to investigate the effects of adropin in serum, potential use as a biochemical biomarker of oxidative stress, and effects on blood pressure in deoxycorticosterone acetate (DOCA) salt hypertensive rats.&#x0D; Methods: Eighteen male Sprague-Dawley rats were divided into two groups: (1) Control (C) and (2) Hypertensive (H). Systolic and diastolic blood pressures (SBP and DBP, respectively), and mean blood pressure (MBP) were measured using the tail-cuff method. At the end of the study, serum endothelin-1 (ET-1), adropin, nitric oxide (NO), total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI) were also analyzed.&#x0D; Results: Significant increases in SBP, DBP, MBP, cardiac hypertrophy index (CHI), and left ventricular hypertrophy index (LVCI) in the H group compared with the C group were found. Serum levels of ET-1, TOS, and OSI were significantly higher in the H group and serum levels of NO, adropin, and TAS were lower than in the C group. A negative correlation between serum adropin levels and the variables SBP, DBP, MBP, TOS, OSI, CHI, and LVHI was found. Adropin levels were positively correlated positively with serum NO levels in both groups.&#x0D; Conclusion: Serum adropin levels decreased in hypertensive DOCA-salt rats. Lower serum adropin levels were found to be significantly associated with hypertension and may play a role in this disease. However, further comprehensive and diverse studies are needed.

Elastic band resistance training increases adropin and ameliorates some cardiometabolic risk factors in elderly women: A quasi-experimental study

BackgroundThe decline in adropin over the aging process is associated with cardiometabolic risks, and resistance training may affect this decline. We hypothesized that elastic band resistance training (EBRT) would be an effective exercise for increasing adropin and improving the cardiometabolic profile in elderly women.MethodsWe randomly assigned 28 overweight elderly women (age = 74.04 ± 4.69 years) into one of two groups, EBRT (n = 14) or control (CON; n = 14), to participate in a 12-week (3d/wk) supervised EBRT program. The serum levels of adropin and cardiometabolic risk factors were evaluated at baseline and after the intervention. The exercise training protocol consisted of three supervised training sessions (55 min) per week for 12 weeks. Data were analyzed using two-way repeated-measures ANOVA and Pearson correlation coefficient.ResultsEBRT significantly increased serum adropin levels (p = 0.026), number of repetitions in the 30-second chair-stand test (p = 0.016), and number of repetitions in the 30-second arm curl test (p = 0.032). Moreover, EBRT significantly decreased serum levels of insulin (p = 0.035), TNF-α (p = 0.046), hsCRP (p = 0.037), and insulin resistance (p = 0.045) as well as body fat percentage (p = 0.023). There were no significant between-group differences (p > 0.05) in glucose, TC, TG, LDL-C, HDL-C, BMI, and WHR; however, glucose, TC, TG, and BMI significantly changed in the EBRT group (within-group). Furthermore, adropin correlated with body fat percentage (p = 0.020) and BMI (p = 0.014) at pretest and with body fat percentage at posttest (p = 0.016), however, delta values were not significantly related. No correlation was observed between adropin and other biomarkers at any stage of the study.ConclusionEBRT can increase serum adropin levels, which has been associated with improved insulin sensitivity, inflammation, body fat percentage, and physical function in overweight elderly women.

DYNAMICS OF ADROPIN AND IRISIN BIOMARKERS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND TYPE 2 DIABETES MELLITUS

summary. A pressing concern of modern medicine is the search for new biomarkers that can influence the development and course of acute myocardial infarction (AMI) in patents with type 2 diabetes mellitus (DM). The aim – To examine the dynamics of adropin and irisin serum levels in diabetic patients with or without AMI complications. Materials and Methods. In total, 134 AMI patients were enrolled. Among 60 examined AMI patients (group I), 41 patients were identified without early cardiovascular (CV) complications of AMI and 19 patients – with complicated AMI. Among 74 AMI patients with type 2 DM (group II), there were 48 patients without early AMI complications and 26 patients with early AMI complications. The control group consisted of 20 otherwise healthy persons. Serum levels of adropin and irisin were measured by enzyme-linked immunosorbent assay. Results. The adropin and irisin serum levels on day 1 of treatment was low in both nondiabetic (I) and diabetic patients (II) compared with those in the control group (p&lt;0.05). On the 10th day of treatment, the levels of adropin in group II patients without early AMI complications were reduced by 13.91 % compared with those in group I (p&lt;0.05). Group II with the presence of early AMI complications showed a reduction of 17.34 % in adropin levels on day 10 compared with group II (p&lt;0.05). On day 10 of treatment, the irisin levels in group II without early AMI complications were reduced by 18.94 % compared with those in group I (p&lt;0.05). In group II with the presence of early AMI complications on the 10th day, the irisin levels were reduced by 23.87 % compared with those in group I (p&lt;0.05). Conclusions. The concentrations of adropin and irisin were significantly low in group II on day 1 and 10 of hospital stay. In the dynamics of treatment on day 10, the levels of adropin and irisin remained low in group II with early CV complications of AMI.

An association between adropin hormone and total testosterone in obese men: a case-control study

BackgroundObesity is associated with low testosterone levels that could be caused by many mechanisms. Adropin, a peptide hormone, its levels are decreased in obesity and its receptors are expressed in the hypothalamus, the pituitary gland, and the testis. Adropin association to total testosterone in obese men is not detected yet. This study tries to find out possible associations between serum levels of adropin, adiponectin, total testosterone, and lipid profile in obese men.MethodsSerum levels of adropin, adiponectin, total testosterone, and lipid profile parameters were measured in 43 obese men and 40 age-matched normal-weight men.ResultsAdropin, adiponectin, and testosterone levels were significantly lower in obese men versus normal-weight men. In all participants, positive correlations between adropin, adiponectin, and total testosterone were detected. Adropin is considered a predictor risk factor for testosterone.ConclusionsThis study suggests a possible causal relationship between adropin and total testosterone which needs further investigation.Trial registrationClincialtrials.gov NCT03724825, registered October 30th, 2018.

Investigation of serum adropin levels and its relationship with hypothalamic atrophy in patients with multiple sclerosis

ObjectiveAdropin is expressed in vascular endothelial cells and regulates nitric oxide (NO) bioavailability by upregulating nitric oxide. In recent years, some studies have revealed its relationship with the pathogenesis of multiple sclerosis (MS). Our aim in this study is to determine serum adropin levels in MS patients and to investigate adropin levels's relationship with hypothalamic atrophy. MethodsA total of 80 people, 40 of whom had MS and 40 of whom were healthy volunteers, were included in the study. Serum samples were taken from all participants. Hypothalamus and pituitary diameters were calculated from magnetic resonance imaging of MS patients. The relationship between serum adropin levels and demographic characteristics, Expanded Disability Status Scale (EDSS), and hypothalamic atrophy were evaluated. ResultsThe levels of adropin were 848,282±139,229 ng/L in patients with MS and 2957,108±284,034 ng/L in the healthy controls. MS patients had significantly lower levels of adropin than the healthy controls (p = 0.003). Adropin has the highest diagnostic value (AUC=0.874, (95% CI, 0,800–0,947) as cut-off value (838.00), sensitivity (80.43%) and specificity (70.64%) in the MS group. In the study, serum adropin levels were not significantly correlated with 3 ventricle diameter (3VD) and pituitary diameter (PD) size (p = 0,968) and no significant relationships were determined between adropin and other clinical parameters. ConclusionAs a potential diagnostic marker, adropin levels were significantly lower in MS patients than in those without. Comprehensive studies are needed to verify this entity.

Relationship between Biomarkers of Carbohydrate, Energy and Adipokine Metabolism in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus

The purpose of the study was to examine the indicators of carbohydrate, energy and adipokine metabolism in acute myocardial infarction patients with or without type 2 diabetes mellitus. Materials and methods. A total of 134 patients with ST-segment elevation acute myocardial infarction in the presence or absence of type 2 diabetes mellitus aged 58.97 ± 7.92 years were examined in the Government Institution “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” and Kharkiv Railway Clinical Hospital No. 1 of the “Center of Healthcare” branch of Public Joint Stock Company “Ukrainian Railway”. The main group (group 1) included 74 patients with acute myocardial infarction and type 2 diabetes mellitus. The comparison group (group 2) was represented by 60 patients with acute myocardial infarction without type 2 diabetes mellitus. The control group was composed of 20 otherwise healthy individuals. Serum concentrations of insulin, adropin, irisin, fatty acid binding protein 4 and C1q/TNF-related protein were measured by enzyme-linked immunosorbent assays. Results and discussion. It was found that the levels of glucose, insulin, HOMA-IR index were increased in acute myocardial infarction patients with or without type 2 diabetes mellitus when compared with the control group (p˂0.05). In acute myocardial infarction patients with type 2 diabetes mellitus, the serum levels of adropin, irisin and C1q/TNF-related protein were significantly lower, while the fatty acid binding protein 4 levels were higher as compared to those in the control group (p&lt;0.05). Acute myocardial infarction patients with type 2 diabetes mellitus demonstrated significantly lower serum concentrations of adropin and C1q/TNF-related protein in comparison with acute myocardial infarction patients without type 2 diabetes mellitus (p&lt;0.05). Negative correlations between blood glucose and adropin (r = -0.499, p&lt;0.001), irisin (r = -0.495, p&lt;0.001), fatty acid binding protein 4 (r = -0.518, p&lt;0.001), between HOMA-IR and adropin (r = -0.304, p&lt;0.02), fatty acid binding protein 4 (r = -0.429, p = 0.001), as well as positive correlations between blood glucose levels and C1q/TNF-related protein (r = 0.435, p = 0.001) were revealed in acute myocardial infarction patients. In acute myocardial infarction patients with type 2 diabetes mellitus, negative correlations were found between blood glucose and adropin (r = -0.504, p&lt;0.001), irisin (r = -0.520, p = 0.03), C1q/TNF-related protein (r = -0.546, p&lt;0.001); between blood insulin and adropin (r = -0.361, p = 0.017), irisin (r = -0.396, p = 0.01), C1q/TNF-related protein (r = -0.361, p = 0.018); between adropin and HOMA-IR (r = -0.508, p = 0.001), C1q/TNF-related protein (r = -0.436, p = 0.003), as well as positive correlation between blood glucose and fatty acid binding protein 4 (r = 0.508, p = 0.007); between blood insulin and fatty acid binding protein 4 (r = 0.501, p = 0.001); between HOMA-IR and fatty acid binding protein 4 (r = 0.516, p&lt;0.001). Conclusion. Characteristics of adropin, irisin, fatty acid binding protein 4 and C1q/TNF-related protein serum levels are evidence of violated energy and adipokine metabolism in both diabetic and non-diabetic patients with acute myocardial infarction. Relationships between adropin, irisin, fatty acid binding protein 4 and C1q/TNF-related protein could indicate involvement of these markers in carbohydrate metabolism

Investigation of serum adropin levels and its relationship with hypothalamic atrophy in patients with multiple sclerosis

Objective Adropin is expressed in vascular endothelial cells and regulates nitric oxide (NO) bioavailability by upregulating nitric oxide. In recent years, some studies have revealed its relationship with the pathogenesis of multiple sclerosis (MS). Our aim in this study is to determine serum adropin levels in MS patients and to investigate adropin levels's relationship with hypothalamic atrophy.Methods A total of 80 people, 40 of whom had MS and 40 of whom were healthy volunteers, were included in the study. Serum samples were taken from all participants. Hypothalamus and pituitary diameters were calculated from magnetic resonance imaging of MS patients. The relationship between serum adropin levels and demographic characteristics, Expanded Disability Status Scale (EDSS), and hypothalamic atrophy were evaluated.Results The levels of adropin were 0.85±0.14 ng/mL in patients with MS and 2.96 ng/mL±0.285 ng/mL in the healthy controls. MS patients had significantly lower levels of adropin than the healthy controls (p = 0.003). Adropin has the highest diagnostic value (AUC=0.874, (95% CI, 0,800–0,947) as cut-off value (838.00), sensitivity (80.43%) and specificity (70.64%) in the MS group. In the study, serum adropin levels were not significantly correlated with 3 ventricle diameter (3VD) and pituitary diameter (PD) size (p = 0,968) and no significant relationships were determined between adropin and other clinical parameters.Conclusion As a potential diagnostic marker, adropin levels were significantly lower in MS patients than in those without. Comprehensive studies are needed to verify this entity.

Determination of adropin, body mass index and other biochemical parameters in Iraqi type II diabetic patients

Evidence suggests a hormone peptide named adropin, is involved in lipid metabolism, insulin resistance, and obesity. However, its role in pathogenesis of type 2 diabetes mellitus (T2DM) is still unclear in humans. Therefore, we investigated whether adropin levels are altered in T2DM patients, and evaluated its association with diabetes- related parameters. Samples which collected from 180 subjects were divided into case group [n = 90] and control groups [n = 90]. The mean age was [43.17 ±11.13] years. Men (n=81) and femanl (n=99) were participated in case-control study. Serum adropin levels were determined by ELISA. The mean serum adropin level was significantly higher [P&lt;0.01] in the control group compared to case group [6.9±1.3 vs. 5.8±1.2] respectively. The result shown there was a significant difference [P-value&lt;0.001] between body mass index and adropin. adropin with high significant negative correlation [P-value&lt;0.001] between adropin and body mass index, fasting blood sugar, glycated hemoglobin, insulin, and homeostatic model assessment for insulin resistance also a significant negative correlation was found between the adropin and low-density lipoprotein, triglyceride, very low-density lipoprotein and no significant with cholesterol, high-density lipoprotein.

The relationship between radial artery spasm and adropin levels in patients undergoing transradial coronary angiography.

Introduction: Transradial coronary angiography (TRA) is associated with a lower incidence of bleeding rate and access site complications and is associated with better outcomes compared to transfemoral angiography. However, radial artery spasm (RAS) is an important limitation of TRA procedures. Little is known regarding the relationship of serum vasodilator and inflammatory markers with RAS. Therefore, the present study aimed to investigate the association between serum adropin level and RAS in patients undergoing TRA. Methods: From February 2020 to January 2021, 39 consecutive patients who underwent elective daiagnostic TRA and experienced RAS during the procedure, and 42 age and sex matched controls who did not experience RAS were prospectively included into the study. The groups were compared regarding serum adropin levels and inflammatory markers.Results: Although adropin levels were found to be lower in the RAS group, this difference was not statistically significant between the the patients with RAS and controls (14.9 vs. 16.1, P=0.105). However, inflammatory parameters monocyte count and MHR (monocyte/HDL cholesterol ratio) were found to be statistically significantly higher in the RAS group compared to controls (P=0.001 and P=0.010, respectively). Moreover, a significant positive correlation was found between the monocyte count and RAS (r:0.360, P<0.001), and between MHR and RAS (r:0.288, P=0.009). Furthermore, multivariate analysis demonstrated that monocyte count (OR:1.671, 95%CI:1.312-2.094, P=0.001) and MHR (OR:1.116, 95%CI:1.054-1.448, P=0.022) were found to be independent predictors of RAS. Conclusion: Serum vasodilator and inflammatory markers may be useful in the prediction of RAS in patients undergoing TRA procedures.

Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus.

In the present study, the relationship between a poor prognosis and adropin levels in diabetic patients with coronavirus disease 2019 was investigated by measuring serum adropin levels and levels of D-dimer, C-reactive protein, and ferritin, which are considered prognostic factors for coronavirus disease 2019. Hundred volunteer participants treated in the Erzurum Regional Training and Research Hospital were included in this study. Serum adropin levels were measured by enzyme-linked immunosorbent assay. The relationship between serum adropin level and C-reactive protein, ferritin, and D-dimer levels was analyzed by correlation analysis. The participants' serum adropin levels differed between the groups (P = .0007). The control group had the highest adropin levels among groups. The lowest adropin levels were in the COVID + diabetes mel- litus group. Adropin levels of diabetes mellitus, COVID, and diabetes mellitus+COVID groups were sig- nificantly decreased when compared to the control (P < .05). There was a significant negative correlation between adropin and C-reactive protein, D-dimer, and ferritin. Adropin can be used as an auxiliary biomarker, a prognostic factor in the early management of coronavirus disease 2019 patients with diabetes mellitus. We think that our study will guide future studies conducted in this field.

Зміни показників енергетичного та ліпідного обміну в пацієнтів на гострий інфаркт міокарда та цукровий діабет 2 типу

The purpose of the study was to examine the indicators of lipid and energy metabolism in patients with acute myocardial infarction in the presence or absence of type 2 diabetes mellitus. Materials and methods. A total of 134 patients with acute ST-segment elevation myocardial infarction in the presence or absence of type 2 diabetes mellitus aged 58.97 ± 7.92 years were examined on the basis of the Intensive Care Department at the Government Institution “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” and the Kharkiv Railway Clinical Hospital No. 1 of the branch “Center of Healthcare” of Public Joint Stock Company “Ukrainian Railway”. Group 1 consisted of 74 patients with acute myocardial infarction and type 2 diabetes mellitus aged 59.42 ± 7.66 years. Group 2 (comparison group) included 60 patients with acute myocardial infarction without type 2 diabetes mellitus aged 58.42 ± 8.25 years. The control group comprised of 20 healthy individuals. All the patients of groups 1 and 2 underwent percutaneous coronary intervention. The study was conducted from September 1, 2018 to December 31, 2020. Serum concentration of adropin and irisin in patients was determined by enzyme-linked immunosorbent assay. Total cholesterol and high-density lipoprotein cholesterol in serum were measured by peroxidase enzymatic method. Triglyceride levels were analyzed by enzymatic colorimetric method. The atherogenic index was calculated by A. M. Klimov formula. Very low-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels were estimated by the Friedewald formula. Results and discussion. Group 1 patients were found to have higher serum triglyceride levels compared with group 2 patients (p&lt;0.05). In groups 1 and 2, total cholesterol and low-density lipoprotein cholesterol levels presented an upward tendency (p˃0.05), and very low-density lipoprotein cholesterol levels were significantly by 4.04 and 2.92 times increased, respectively, as compared to the control group (p&lt;0.05). The serum adropin levels were significantly lower in patients with acute myocardial infarction and type 2 diabetes mellitus in comparison to those in patients with acute myocardial infarction without type 2 diabetes mellitus (p&lt;0.05). There was a significant decrease in the concentrations of adropin and irisin in both groups compared with the control group (p&lt;0.05). Conclusion. Characteristics of changes in adropin and irisin levels suggest an energy homeostasis imbalance in acute myocardial infarction in the presence or absence of type 2 diabetes mellitus that may significantly increase the risk of cardiovascular complications of acute myocardial infarction in this category of patients. The relationship between adropin, irisin and lipid profile may indicate the influence of these markers on lipid metabolism

Characterizing the Therapeutic Potential of the Adropin‐GPR19 Signaling Pathway in MAFLD

Obesity is the second leading cause of preventable death in the United States, and serves as a fundamental risk factor in various pathologies including metabolic‐associated fatty liver disease (MAFLD). The cellular and molecular mechanisms that drive obesity‐related disease in different tissues are not fully elucidated, and this represents an impediment to the development of effective and efficient treatments. Adropin is a nutritionally regulated liver‐ and brain‐derived peptide hormone that modulates metabolic homeostasis in several tissues. Adropin levels are significantly reduced in obese human subjects, and this decrease is linked to increased adiposity, impaired glucose homeostasis, and liver injury. Recent reports show that MAFLD patients exhibit a marked decrease in serum adropin levels, however the functional significance of this is unknown. Various studies suggest that a class A orphan G‐coupled protein receptor, GPR19, mediates adropin signal transduction, therefore we hypothesized that GPR19 may be the putative cellular receptor that permits adropin function in the liver. To investigate this, we used a novel whole‐body GPR19 knockout mouse to perform a preliminary characterization of the effects of GPR19 depletion on hepatic and whole‐body physiology. Using in vivo metabolic approaches, we report that GPR19 KO mice exhibit glucose intolerance, altered hepatic energy metabolism, and histological liver injury. Together, these data suggest that GPR19 KO mice display pathogenic events that promote a MAFLD phenotype, indicating that GPR19 may be critical for the protective effects of adropin signaling in the liver. These findings further define the fundamental role of the adropin‐GPR19 signaling pathway in the regulation of metabolic homeostasis, and thus highlight a potential target for therapeutic interventions in MAFLD.

Role of serum adropin as a novel biomarker in primary knee osteoarthritis patients: Relation to the functional status, radiographic grading and ultrasonographic findings

BackgroundKnee osteoarthritis (KOA) may lead to disabilities and affect work and daily activities. There is no specific blood test for its early diagnosis. Serum adropin is however a promising biomarker. Aim of the workTo determine the levels of serum adropin in primary KOA andassess its relation with the different radiographic grades of the disease. Patients and methodsA total of 40 primary KOA patients (64 affected knees) and 20 healthy control participated in this study. KOA grades was assessed using ultrasonography (US) and X-ray according to KL grading system. Serum adropin levels were measured. ResultsKOA was bilateral in 24 (60%) patients and knee effusion was present in 46 knees (71.9%). Serum adropin level in KOA patients (46.3 ± 27.9 pg/ml) was significantly lower than in controls (76.5 ± 27.2 pg/ml) (p < 0.00001). Serum adropin was lower in females than in males in patients (40.2 ± 17.7 pg/ml vs 75.2 ± 47.2 pg/ml; p = 0.0016). Serum adropin has significant negative correlation with the KL radiographic grading (r = -0.54, p = 0.0003).At cut off value of 54 and an AUC = 0.85, serum adropin could significantly distinguish between patients and controls (p < 0.05) at a sensitivity of 80%, specificity 90%. ConclusionsSerum adropin levels were significantly low in KOA patients with specificity of 90% and sensitivity of 80%, with a negative significant correlations with the degree of radiographic severity evaluated by KL grading scale and ultrasound. These findings suggest that low serum adropin levels could be a sensitive and specific test for the detection of KOA.